ReviewAsia-Pacific journal of clinical oncology2026
Personalized Cancer Vaccines in the Clinical Trial Pipeline.
Review in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Past achievements and future perspectives of personalized vaccines and the role of dendritic cells.Immunologic research · 2026Review
- Personalized Cancer Vaccines in the Clinical Trial Pipeline.Asia-Pacific journal of clinical oncology · 2026Review
- Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity.The Lancet regional health. Europe · 2026Review
- Identification of Glycoprotein Biomarkers in Breast Cancer by MALDI.Life (Basel, Switzerland) · 2026Review
- Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non-profit communities.
methodsA dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database as of November 25, 2024. We conducted an analysis of the studies based on sponsors, conditions, phases, types of vaccines, and global geographic distribution.
resultsThe majority of trials focused on peptide vaccines (40%) and dendritic cell vaccine (19%), targeting solid tumors, brain, pancreatic and breast cancers, among others. Phase 1 trials dominated the landscape, accounting for over 90% of studies, with significant activity in the United States (44%) and China (24%). Industry sponsors backed 22% of studies. Active trials represented 72% of the dataset, reflecting ongoing research efforts in this field. Enrollment sizes varied widely, ranging from small exploratory cohorts of fewer than 10 participants to larger-scale trials enrolling up to 700 patients. Completed clinical trials evaluating personalized neoantigen vaccines across various cancer types showed that vaccines were generally well-tolerated, elicited strong T-cell responses, and resulted in promising clinical outcomes such as tumor shrinkage or prolonged progression-free survival, particularly in melanoma, glioblastoma, and urothelial cancer, although no universal cure was demonstrated.
conclusionsThere is a broad early-stage pipeline of personalized cancer vaccines currently being tested in clinical trials for various cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.